Safety, Pharmacokinetics, and Efficacy of Topical 3% Amphotericin B Cream for the Treatment of Uncomplicated Cutaneous Leishmaniasis in Colombia

Trial Profile

Safety, Pharmacokinetics, and Efficacy of Topical 3% Amphotericin B Cream for the Treatment of Uncomplicated Cutaneous Leishmaniasis in Colombia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Amphotericin B (Primary)
  • Indications Cutaneous leishmaniasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Anfoleish
  • Most Recent Events

    • 25 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 17 Feb 2016 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 17 Feb 2016 Planned primary completion date changed from 1 Feb 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top